Monocyte differentiation involves the participation of lineage-restricted transcription factors, although the mechanisms by which this process occurs are incompletely defined. Within the hematopoietic system, members of the Kruppellike family of factors (KLFs) play essential roles in erythrocyte and T lymphocyte development. Here we show that KLF4/GKLF is expressed in a monocyte-restricted and stage-specific pattern during myelopoiesis and functions to promote monocyte differentiation. Overexpression of KLF4 in HL-60 cells confers the characteristics of mature monocytes. Conversely, KLF4 knockdown blocked phorbol ester-induced monocyte differentiation. Forced expression of KLF4 in primary common myeloid progenitors (CMPs) or hematopoietic stem cells (HSCs) induced exclusive monocyte differentiation in clonogenic assays, whereas KLF4 deficiency inhibited monocyte but increased granulocyte differentiation. Mechanistic studies demonstrate that KLF4 is a target gene of PU.1. Consistently, KLF4 can rescue PU.1À/À fetal liver cells along the monocytic lineage and can activate the monocytic-specific CD14 promoter. Thus, KLF4 is a critical regulator in the transcriptional network controlling monocyte differentiation.
Introduction
Hematopoietic stem cells (HSCs) may generate committed progenitor cells that lose the capacity to self-renew and ultimately differentiate along a specific lineage to form mature blood cells. Control of hematopoiesis is a complex process requiring the coordinated expression of stage-specific transcription factors that allow for subsequent induction of lineage-restricted genes and cell surface receptors Friedman, 2002) . Cytokines and growth factors may then increase lineage-committed progenitor cell populations depending, in part, on the expression levels of lineage determination transcription factors. In the myeloid pathway, mature monocytes and granulocytes arise from bipotential granulocyte/macrophage progenitors (GMPs) that, in turn, arise from multipotential common myeloid progenitors (CMPs); CMPs may also give rise to bipotential megakaryocyte/erythrocyte progenitors (MEPs) (Akashi et al, 2000; Traver et al, 2001) . Identification of transcription factors that participate in controlling progenitor cell fate decisions in the myeloid pathway has been of considerable interest with therapeutic implications for a variety of conditions including leukemia, anemia, and chronic inflammatory diseases, among others.
Gene knockout experiments in mice have identified several transcription factors as critical regulators of different aspects of myeloid development Friedman, 2002) . For example, disruption of the Ets transcription factor PU.1 in mice resulted in multiple hematopoietic defects, including a reduction of not only mature macrophages and granulocytes, but also B and T lymphocytes and NK cells (Scott et al, 1994; McKercher et al, 1996; Colucci et al, 2001) . Indeed, the presence of PU.1 is required for the development of CMPs and common lymphoid progenitors (CLPs) from HSCs (Iwasaki et al, 2005) . These findings place PU.1 upstream in the transcriptional hierarchy of specifying progenitor cell fate and raise the possibility that additional factors may participate at specific stages to restrict lineage commitment along single myeloid pathways. For example, GATA-1, a transcription factor essential in specifying progenitors along erythrocyte, megakaryocyte, mast cell, and eosinophil lineages (at the expense of monocyte/granulocyte lineages), interacts with PU.1 to inhibit its function and vice versa (Rekhtman et al, 1999; Zhang et al, 1999; Nerlov et al, 2000) . Examples of this type of mutual antagonism exist throughout the hematopoietic system (Orkin, 2000) . The balance between monocyte and granulocyte differentiation may be regulated, in part, by mutual antagonism between PU.1 and the CCAAT enhancer-binding protein-a (C/EBP-a).
C/EBP-a-deficient mice exhibit a complete block in neutrophil differentiation with normal monocyte maturation . Recent mechanistic studies have revealed that C/EBP-a physically interacts with PU.1 and may contribute to the specification of myeloid progenitors to the granulocyte lineage depending on the expression ratio of these two factors (Reddy et al, 2002; Dahl et al, 2003) (Radomska et al, 1998; Reddy et al, 2002) . Interestingly, mice carrying a graded reduction of PU.1 expression to 20% of normal levels develop acute myeloid leukemia (Rosenbauer et al, 2004) . Thus, stagespecific expression of various transcription factors helps dictate not only cell fate decisions in the myeloid lineage, but also the development of malignant transformation (Tenen, 2003; Rosenbauer et al, 2004) .
The Kruppel-like family of transcription factors (KLFs) are critical regulators of cellular development, growth, and differentiation. (Bieker, 1996; Feinberg et al, 2004) . Two examples highlight the critical role of this family of genes in hematopoietic development. KLF1, or EKLF (erythroid Kruppel-like factor), is expressed primarily in red blood cells. Gene targeting experiments revealed that KLF1 is necessary for g-to b-globin switching during erythrocyte development (Nuez et al, 1995; Perkins et al, 1995) . KLF2, or LKLF (lung Kruppel-like factor), is highly expressed in T cells, and targeted disruption of KLF2 verified an essential role for this factor in programming and maintaining naïve T-cell quiescence (Kuo et al, 1997) . Because of the importance of KLF1 and KLF2 in different hematopoietic lineages, we hypothesized that a related Kruppel-like zinc-finger (ZF) protein may regulate the differentiation of precursor cells along the monocyte/macrophage cell pathway. Using a lowstringency homology screening strategy, we identified KLF4 as being highly expressed in monocytes. KLF4 was initially identified in the epithelial lining of the gut and skin (GarrettSinha et al, 1996; Shields et al, 1996) and gene targeting experiments have verified a critical role for this factor in these tissues (Segre et al, 1999; Katz et al, 2002) as well as in embryonic cells (Takahashi and Yamanaka, 2006) and cornea (Swamynathan et al, 2006) . Recently, we demonstrated that KLF4 can regulate iNOS expression and TGF-b signaling in activated macrophages (Feinberg et al, 2005) and Noti et al (2005) identified that KLF4 can repress the CD11d promoter in leukemic cell lines. However, the functional role of KLF4 in myeloid cell development has not been defined.
Herein, we found that among myeloid cells, KLF4 is expressed principally in monocytes and is induced in a stage-specific manner during myelopoiesis. Overexpression of KLF4 in promyelocytic HL-60 cells or in primary CMPs or HSCs from bone marrow restricts these cells along the monocyte/macrophage pathway at the expense of other myeloid lineages and confers the morphologic, genetic, and functional characteristics of a mature monocyte. We further show that KLF4 is a downstream target gene of PU.1 and is capable of binding to the monocyte-specific CD14 promoter. Taken together, these data support an important role for KLF4 as a key transcriptional regulator of monocyte differentiation.
Results

Identification of KLF4
The full-length cDNA of KLF4 was identified through low-stringency homology screening of a rat monocyte/macrophage cDNA library using the ZF domain of KLF1/EKLF as a probe. Analysis of the 1422-base pair open reading frame revealed a 474-amino-acid protein with three Cys 2 /His 2 zinc fingers at the C-terminus and a proline-rich N-terminus (data not shown). A GenBank search of three out of nine clones isolated revealed that our factor is identical to the rat homolog of GKLF/EZF, also known as KLF4 (Garrett-Sinha et al, 1996; Shields et al, 1996; Higaki et al, 2002) .
Expression of KLF4 in human hematopoietic cell lines
To understand the pattern of KLF4 expression in human hematopoietic cells, we analyzed total RNA isolated from primary human peripheral blood monocytes and seven human hematopoietic cell lines by Northern blotting ( Figure 1A) . A single, intense 3.5-kb band corresponding to KLF4 was detected in RNA from human peripheral blood monocytes, the monocyte-like THP-1 cell line, and the histiocytic U-937 cell line. In contrast, KLF4 mRNA was undetectable in RNA derived from the HeL (erythrocyte), Jurkat (T lymphocyte), Raji (B lymphocyte, immature), and U-266 (B lymphocyte, mature) cells. To assess the expression of KLF4 protein in myeloid cells, we harvested total cell extracts from human peripheral blood monocytes and THP-1, U-937, and HL-60 cells and performed Western blot analysis with a polyclonal KLF4 antiserum. KLF4 protein was detected in human peripheral blood monocytes and THP-1 and U-937 cells but not in promyelocytic HL-60 cells ( Figure 1B) . Thus, among hematopoietic cells, KLF4 mRNA and protein are expressed in monocytes and monocyte-like cell lines.
As shown in Figure 1A and B, KLF4 is expressed in several cell lines committed to the monocytic lineage (THP-1 and U-937 cells). In contrast, KLF4 is not expressed in the uncommitted bipotential cell line HL-60. These cells can differentiate along the monocytic or the granulocytic pathway when treated with 12-O-tetradecanoyl phorbol-13 acetate (TPA) or retinoic acid (RA), respectively. Therefore, we reasoned that HL-60 cells would provide a useful in vitro system for studying the role of KLF4 in monocytic differentiation. First, we determined whether TPA and RA treatment led to KLF4 expression in HL-60 cells. KLF4 mRNA was undetectable in HL-60 control cells (vehicle alone) and in cells treated with RA, but was markedly induced in cells treated with TPA ( Figure 1C ). In contrast, CD11b mRNA (a marker of differentiation that does not distinguish monocytes from granulocytes) was induced by TPA as well as RA. Taken together, these observations demonstrate that KLF4 expression is restricted to monocytes but not granulocytes ( Figure 1C ).
KLF4 induces a monocytic phenotype in HL-60 cells
To determine whether KLF4 participates directly in monocytic differentiation, we retrovirally infected HL-60 cells with either full-length KLF4 or an empty virus control (EV) and analyzed the cells for various myeloid markers 4 days later. Exogenous expression of KLF4 was verified by Northern and Western analyses (Figure 2A and B). In comparison with EV-infected cells, we noticed a marked induction of the myeloid markers CD11b and CD14 ( Figure 2A ). Consistent with a monocytic phenotype, KLF4 expressing cells also expressed higher levels of c-fms ( Figure 2A ). To quantitate the induction of various hematopoeitic cell surface markers, we performed fluorescence-activated cell sorter (FACS) analyses on both EV-and KLF4-infected HL-60 cells. In comparison with EV-infected cells, KLF4 induced monocytic markers for CD11b (81.7 vs 2.6%) and CD14 (75.8 vs 6.5%), while having no effect on the granulocytic marker CD66b or the lymphocytic markers CD3 and CD19 ( Figure 2C ). As expected, there were no significant differences in the expression of cell surface markers between the GFP-negative cell populations ( Figure 2D ). Thus, KLF4 induces monocytic but not granulocytic or lymphocytic markers in HL-60 cells.
Both monocytes and granulocytes bear characteristic morphologic features. To determine if KLF4 overexpression affects cellular morphology, we performed cytospin analyses. As shown in Figure 2E , HL-60 cells infected with KLF4 exhibited marked morphologic changes. In comparison with EVinfected cells, the KLF4-overexpressing cells are larger, with increased cytoplasmic size and smaller more condensed indented nuclei. In addition, KLF4-overexpressing cells bear ruffled edges, are less basophilic, and contain cytoplasmic vacuoles. These characteristics are consistent with a monocytic phenotype in these cells (Collins, 1987) . To verify whether KLF4 directly participates in regulating PU.1 and monocytic gene expression, we used morpholino antisense oligonucleotides to knockdown KLF4 expression during HL-60 cell TPA-induced monocytic differentiation. As shown in Figure 2F and G, in comparison with the nonspecific control morpholino, KLF4 knockdown resulted in a significant reduction in PU.1 and monocytic differentiation markers, as well as impairment of cell adhesion and cytoplasmic spreading. Furthermore, KLF4 overexpression induced HL-60 cell G1-growth arrest, p21 WAF1 , and inhibited cyclin D1 ( Figure  2H-J) . Finally, we demonstrate that overexpression of KLF4 allows precursor HL-60 cells to become functionally mature monocytes capable of adhering to a stimulated endothelial monolayer and undergoing phagocytosis (Supplementary Figure 1) . Taken together, these data indicate that KLF4 is a critical regulator of HL-60 monocytic differentiation.
KLF4 transactivates the monocytic CD14 promoter
To define the mechanism(s) underlying the ability of KLF4 to induce expression of monocytic markers, we performed transient transfection studies using the proximal À474-bp CD14 in HeLa cells. We observed an B30-fold induction of the CD14 promoter by KLF4 ( Figure 3A ). In contrast, KLF4 repressed the smooth muscle cell-specific promoter SM-aactin ( Figure 3A ). To assess whether other KLF family members are capable of activating a myeloid promoter, we cotransfected KLF4, KLF2/LKLF, KLF5/IKLF, or KLF15 with the monocytic-specific CD14 promoter. As demonstrated in Figure 3B , KLF4 induced the CD14 promoter by 35-fold, whereas KLF2, KLF5, or KLF15 transactivated the CD14 promoter no more than the ZF domain of KLF4 alone. Finally, the induction by KLF4 required both the ZF DNAbinding domain of KLF4 as well as the non-ZF domain (aa 1-388), as each construct alone had little effect on the CD14 promoter ( Figure 3B ). Collectively, these data suggest that in comparison with several other KLF family members, KLF4 is able to promote the monocytic differentiation marker CD14 and this requires intact KLF4.
KLF4 induces the CD14 promoter through DNA binding
To better define how KLF4 may induce monocytic-specific markers, we analyzed the À474-bp CD14 promoter, as it is active almost exclusively in monocytes/macrophages. Analysis of this promoter region revealed two potential KLF4-binding sites (open boxes, Figure 3C ). One of these sites (À288 to À278) contains three partially overlapping KLFbinding sites. A 5 0 deletion downstream to this site (À277-bp CD14 promoter) revealed a B48% decrease in KLF4 transactivation (data not shown). Site-directed mutation of the proximal (À88 to À83) KLF site within the À474-bp CD14 promoter also resulted in a B61% reduction of activity by KLF4 ( Figure 3C ). However, when the two KLF sites were mutated within the À474-bp CD14 promoter, we found that there was an B84% reduction in activity by KLF4 ( Figure 3C ). These data suggest that KLF4 can transactivate the CD14 promoter by binding to KLF sites.
Members of the Kruppel-like family bind to specific DNA elements (5 0 -CNCCC-3 0 ) to exert their function. To assess the ability of KLF4 to bind DNA within the À474-bp CD14 promoter, we performed electrophoretic mobility shift assays using Flag-tagged GST-KLF4 and a radiolabeled oligonucleotide probe containing the KLF sites (À288 to À278) and (À92 to À82) of the À474-bp CD14 promoter. As shown in Figure 3D , in comparison to GST alone, incubation of GST-KLF4 resulted in a dominant DNA-protein complex (arrow) that bound to each of these sites. These complexes are specific as they cannot bind to mutated radiolabeled probes and can be supershifted with an a-Flag antibody. Thus, KLF4 is able to bind to KLF sites within the À474-bp CD14 promoter.
Expression of KLF4 mRNA in primary bone marrowderived myeloid progenitor cells To assess KLF4 expression in primary progenitor cells, we isolated several populations of myeloid progenitors or HSCs by multicolor FACS system, as described previously (Akashi et al, 2000; Miyamoto et al, 2002) . As shown in Figure 4A (left), real-time PCR analyses revealed that KLF4 mRNA expression progressively increased from the HSC to the GMP stage, whereas it decreased in MEPs. Expression of the Ets transcription factor PU.1 also increased in a similar manner as KLF4 from the HSC to the GMP stage, with weaker expression in MEPs ( Figure 4A , right). These findings raise the possibility that KLF4 may participate in regulating myeloid differentiation.
KLF4 overexpression restricts CMPs or HSCs to the monocytic lineage
Because KLF4 expression is induced in a stage-specific manner during primary myeloid differentiation, we hypothesized that overexpression of KLF4 in CMPs may promote monocytic differentiation at the expense of other lineages. To address this, we retrovirally infected CMPs with either EV (Ctrl) or KLF4, isolated the GFP positive cells ( Figure 4B ), and allowed them to grow in methylcellulose medium in a cocktail of cytokines capable of differentiating the CMPs along each of the lineages after 5 days of culture. Remarkably, overexpression of KLF4 in CMPs resulted in the preferential commitment and differentiation of nearly all cells to the monocytes/macrophage lineage in comparison with EV (Ctrl) cells ( Figure 4C ). Furthermore, this was accompanied by a reduction of cells from other lineages (granulocytes, erythrocytes, or megakaryocytes). Light microscopy of Electrophoresis mobility shift assays (EMSAs) were performed using GST or GST-KLF4-Flag-purified protein on the proximal and distal KLF DNA-binding sites. A specific band (arrow) for KLF4 demonstrates binding only to a radiolabeled oligonucleotide probe containing either the wild-type KLF proximal (À92 to À82) or distal (À288 to À278) site, but not to a mutant site, and may be supershifted in the presence of an a-Flag antibody.
KLF4-overexpressing cells demonstrated many adherent cells, and cytospun preparations verified that these cells had enlarged vacuolated cytoplasms with condensed, often indented, nuclei-morphological characteristics typical of mature monocytes and macrophages in these assays ( Figure 4D ) (Akashi et al, 2000) . A similar pattern of monocyte-restricted differentiation occurred when KLF4 was overexpressed in HSCs ( Figure 4F ). In contrast, PU.1 overexpression in either CMPs or HSCs promoted both monocyte and granulocyte differentiation ( Figure 4E and F).
KLF4 rescues monocyte differentiation in PU.1-null cells
To assess if KLF4 is capable of monocyte differentiation independent of PU.1, we used fetal liver cells from neonatal PU.1-null mice. These cells give rise to a reduced number of hematopoietic progenitors and mature myeloid cells; however, in the presence of IL-3, they can form neutrophils but not monocytes/macrophages (Anderson et al, 1999) . In PU.1-null fetal liver cells, expression of KLF4 mRNA and protein is absent in comparison with wild-type bone marrow-derived macrophages ( Figure 5A ). To assess whether KLF4 requires PU.1 to induce monocyte differentiation, we retrovirally overexpressed EV (Ctrl) or KLF4 in PU.1-null fetal liver cells and grew them in methylcellulose for 7 days with GM-CSF. These cells were also transduced with PU.1 as a positive control, as previous reports have shown that rescue with PU.1 allows the formation of mature monocytes/macrophages and neutrophils, as well as the cell surface markers CD11b and CD45 (Anderson et al, 1999 (Anderson et al, , 2001 . As demonstrated in Figure 5B , KLF4 was capable of inducing these differentiation markers in the PU.1-deficient cells to a level similar as that achieved by PU.1 alone. Consistently, KLF4-overexpressing cells possessed morphological features of monocytes in comparison with EV control cells (Supplementary Figure 2) . Indeed, PCR analyses demonstrated that KLF4 markedly induced expression only of M-CSFR, whereas PU.1 induced both M-CSFR and G-CSFR ( Figure 5C ). Taken together, these results suggest that KLF4 can rescue the differentiation defect of PU.1-null myeloid cells along the monocyte/macrophage pathway.
KLF4 is a target gene of PU.1
The fact that KLF4 expression is absent in PU.1-null cells raised the possibility that KLF4 may be a downstream target of PU.1 in the transcriptional hierarchy of specifying macrophage cell fate. To assess whether PU.1 overexpression can induce KLF4, we retrovirally infected HL-60 cells with emptyvirus GFP-control (EV) or PU.1-GFP for 5 days. As shown in Figure 5D , in comparison to EV, PU.1-overexpressing cells induced KLF4 mRNA expression. Conversely, cells deficient in PU.1 have markedly decreased expression of KLF4 ( Figure 5A; Supplementary Figure 3) . PU.1 is a member of the ets family of transcription factors that bind to consensus GGAA-like motifs (Rosenbauer et al, 2005) . Examination of the KLF4 promoter identified a potential PU.1 site at À118 bp.
To assess whether PU.1 can induce the KLF4 promoter, cells were cotransfected with pcDNA3 or PU.1, in the presence of the wild-type KLF4 promoter or the KLF4 promoter bearing a mutant PU.1 site (KLF4 pro-Mut-PU.1). As demonstrated in Figure 5E , PU.1 induced the KLF4 promoter B15-fold. However, in the presence of a KLF4 pro-Mut-PU.1, this induction was markedly attenuated to B3.8-fold. To determine whether this site is capable of binding PU.1, we performed gel shift studies using a GST-PU.1 fusion protein.
As shown in Figure 5F , GST-PU.1, but not GST alone, bound to this site and was abolished in the presence of a radiolabeled mutant PU.1 site. Chromatin immunoprecipitation (ChIP) studies also verified that PU.1 can bind to the KLF4 promoter ( Figure 5G ). To gain further insight, we validated these observations using quantitative real-time PCR (qPCR). As shown in Supplementary Figure 4 , only primer sets inclusive of the PU.1 site demonstrated binding to the KLF4 promoter; in addition, no PU.1 binding was identified using an IgG control antibody or an irrelevant antibody to c-Jun. Taken together, these data indicate that KLF4 is a PU.1 target gene that helps specify monocyte commitment and differentiation.
KLF4 deficiency alters myeloid differentiation
Because overexpression of KLF4 exclusively promoted monocyte/macrophage differentiation in CMPs and HSCs, we hypothesized that KLF4 deficiency may reduce monocytes and possibly shift CMP differentiation toward granulocytes.
To assess this, we isolated CMPs derived from wild-type or Klf4loxP mice (Katz et al, 2005) and retrovirally infected them with retrovirus containing Cre recombinase or EV (Ctrl). GFP þ cells were isolated by FACS and subsequently grown in culture for up to 7 days in the presence of a cocktail of cytokines capable of differentiating the cells along all myeloid pathways (Akashi et al, 2000) . CMPs derived from wild-type mice showed no differences in myeloid differentiation toward monocytes or granulocytes (data not shown).
In contrast, CMPs-overexpressing Cre recombinase from Klf4loxP mice showed a marked reduction of B56% in the formation of mature monocytes, whereas granulocyte formation was increased by B36% ( Figure 6A and B) . Similarly, Cre-excision of KLF4 in HSCs from Klf4loxP resulted in a B40% reduction in the number of monocytes and an B41% increase in granulocyte formation ( Figure 6C and D) . Collectively, these findings indicate that varying levels of KLF4 may dynamically regulate the balance between monocytes and granulocytes.
Discussion
We have shown here that KLF4 is a novel regulator of myeloid differentiation. In support, KLF4 is expressed in a monocyte-restricted and stage-specific pattern during myelopoiesis, programs myeloid progenitor cell fate towards the monocyte lineage, and acts as a PU.1 target gene. Moreover, KLF4 deficiency is associated with impaired monocyte and enhanced granulocyte differentiation in bone marrow clonogenic assays. Mechanistically, KLF4 may mediate these effects by inducing monocytic-specific promoter activity. These findings represent a new paradigm involving KLF4 in the regulatory network of monocyte development.
KLFs in hematopoiesis
Kruppel-like factors have been shown to play critical roles in various aspects of hematopoietic cell differentiation (Bieker, 1996; Feinberg et al, 2004) . For example, the founding member, KLF1, is highly expressed in erythrocyte lineages and gene deletion experiments demonstrated an essential role for KLF1 in b-globin synthesis (Nuez et al, 1995; Perkins et al, 1995) . KLF2 is induced during the differentiation of immature double positive T cells (CD4 þ CD8 þ ) to single positive T cells (CD4 þ or CD8 þ ), which circulate in the bloodstream. Indeed, targeted disruption of KLF2 verified an essential role for this factor in programming the quiescent phenotype of single positive T cells (Kuo et al, 1997) . Recently, KLF2 was also shown to regulate T-cell egress from the thymus and peripheral trafficking (Carlson et al, 2006) . KLF3/BKLF was originally identified after screening a mouse erythroleukemia cDNA library, and has a broad tissue expression pattern (Crossley et al, 1996) . Interestingly, KLF3 expression was markedly and specifically reduced in erythroid cells from KLF1À/À mice. In contrast to KLF1À/À mice, preliminary data suggest that KLF3À/À mice have a less severe defect in hematopoiesis and display a myeloproliferative disorder (Perkins et al, 1997) . Collectively, these observations suggest that KLFs can have profound, often cell type-specific, phenotypic effects within the hematopoietic system. The studies presented in this paper extend a participatory role of KLF proteins in monocyte development.
KLF4 as a PU.1 target gene: role of transcription factor gradients for specifying myeloid differentiation
The presence of PU.1 is required for the formation of both CMPs and CLPs, raising the possibility that gradients of specific transcription factors may help direct lineage commitment at various stages (Rosenbauer et al, 2005) . For example, GATA-1 antagonizes PU.1 to drive megakaryocyte/erythrocyte maturation (Rekhtman et al, 1999) , whereas C/EBP-a antagonizes PU.1 to promote granulocytic maturation (Dahl et al, 2003) . Consistently, loss of C/EBP-a in mice blocks granulocyte maturation and is important for the transition of the CMP to GMP stage; however, after the GMP stage, loss of C/EBP-a has no effect on granulocyte or monocyte formation, indicating that instructive cues or 'progenitor priming' for monocyte versus granulocyte development likely occur before GMP differentiation (Zhang et al, 2004) . Because PU.1-null mice have defects in multiple cell lineages (Scott et al, 1994; McKercher et al, 1996; Colucci et al, 2001) , it raises the possibility that downstream factors may be necessary for sustaining progenitors along the monocytic pathway. Several lines of evidence support KLF4 as an important target gene of PU.1 in this process: (1) KLF4 expression was induced in an analogous manner as PU.1 in the CMP-to-GMP transition ( Figure 4A ); (2) KLF4 modulated the balance between monocytes and granulocytes with exclusive monocyte differentiation in CMPs, HSCs, and the bipotential HL-60 cell line ( Figures 2 and 4) ; (3) KLF4 expression is absent in PU.1À/À fetal liver hematopoietic progenitors and overexpression of KLF4 endowed PU.1À/À progenitors to express M-CSFR, whereas rescue of these cells with PU.1 induced both M-CSFR and G-CSFR ( Figure 5A -C); (4) overexpression of PU.1 induced KLF4 expression in HL-60 cells ( Figure 5D ); (5) mutation of a PU.1 site in the proximal KLF4 promoter significantly inhibited the ability of PU.1 to transactivate the promoter ( Figure 5E ); and (6) gel shift and ChIP studies both verify that PU.1 can bind to the proximal KLF4 promoter (Figure 5F and G; Supplementary Figure 4) . Taken together, based on these observations, we propose a transcriptional hierarchy whereby PU.1 induces KLF4, which can, in turn, promote monocyte and antagonize granulocyte development. Indeed, accumulating evidence supports a role for the order of expression of transcription factors in controlling hematopoietic lineage commitment (Iwasaki et al, 2006) .
Role of KLF4 in hematopoiesis and implications for leukemogenesis
During hematopoiesis, KLF4 is expressed in a stage-specific manner-with highest expression in GMPs and lowest expression in HSCs and MEPs ( Figure 4A ). Disruption of KLF4 at either the HSC or CMP stage reduced the number of monocytes with a shift toward increased granulocytes, whereas overexpression of KLF4 induced only monocyte differentiation at both of these stages (Figures 4 and 6) .
Because the relative levels and order of transcription factor expression can have profound effects in cell lineage fate, dysregulation of KLF4 may be important in leukemogenesis.
Mice with a genetic deletion of the PU.1 URE (a.k.a PU.1-knockdown mice), develop acute myeloid leukemia as a result of an B80% reduction in PU.1 expression and absence of M-CSFR and GM-CSFR expression (Rosenbauer et al, 2004) . Recent analyses of HSCs from preleukemic PU.1-knockdown mice demonstrate a reduction of a number of transcriptional regulators including KLF4 (approximately À2.73-fold) (Steidl et al, 2006) , raising the possibility that altered ratios of PU.1/KLF4 may influence leukemic transformation. Indeed, JunB expression was also reduced (approximately À1.71) in PU.1-knockdown HSCs and overexpression of JunB rescued the myelomonocytic block and leukemogenic properties in these cells (Steidl et al, 2006) . Although our data suggest that KLF4 can promote monocyte differentiation independent of PU.1 as shown in Figure 5 , we cannot rule 
